151 related articles for article (PubMed ID: 37646965)
1. Vimentin promotes glioma progression and maintains glioma cell resistance to oxidative phosphorylation inhibition.
Liu Y; Zhao S; Chen Y; Ma W; Lu S; He L; Chen J; Chen X; Zhang X; Shi Y; Jiang X; Zhao K
Cell Oncol (Dordr); 2023 Dec; 46(6):1791-1806. PubMed ID: 37646965
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 promotes glioma progression and maintains its mitochondrial inhibition resistance.
Liu Y; Chen Y; Wang F; Lin J; Tan X; Chen C; Wu LL; Zhang X; Wang Y; Shi Y; Yan X; Zhao K
Discov Oncol; 2023 Aug; 14(1):161. PubMed ID: 37642765
[TBL] [Abstract][Full Text] [Related]
4. Pyroptosis-Related Gene Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Glioma.
Zhang Y; Zhang C; Yang Y; Wang G; Wang Z; Liu J; Zhang L; Yu Y
Front Cell Dev Biol; 2022; 10():862493. PubMed ID: 35547808
[No Abstract] [Full Text] [Related]
5. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
6. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
7. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
8. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
9.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
10. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
11. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
12. High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.
Guo Q; Gao X; Li J; Liu Y; Liu J; Yang H; Cui M; Zhang M; Duan L; Ma X
Sci Rep; 2023 Mar; 13(1):3820. PubMed ID: 36882457
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
14. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
[TBL] [Abstract][Full Text] [Related]
16. High LYRM4-AS1 predicts poor prognosis in patients with glioma and correlates with immune infiltration.
Wang HY; Xie Y; Du H; Luo B; Li Z
PeerJ; 2023; 11():e16104. PubMed ID: 37810780
[TBL] [Abstract][Full Text] [Related]
17. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
18. High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma.
Yu K; Ji Y; Liu M; Shen F; Xiong X; Gu L; Lu T; Ye Y; Feng S; He J
Front Immunol; 2022; 13():881453. PubMed ID: 35663965
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
20. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
